The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

6 Nov 2017 07:00

RNS Number : 5754V
Benchmark Holdings PLC
06 November 2017
 

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Appointment of Non-Executive Directors

 

Benchmark strengthens the board bringing in leading industry and commercial expertise

 

Benchmark, the aquaculture biotechnology and food chain sustainability business, announces the appointment of Hugo Wahnish and Yngve Myhre as Non-Executive Directors of the Company with immediate effect.

 

Hugo Wahnish (65) has over 35 years of experience in the animal health and pharmaceuticals industry, firstly with GlaxoSmithKline, and more recently with Merck during a period of major growth in the organisation. Hugo held the post of Chief Commercial Officer Animal Health at Merck, having responsibility for Merck's commercial operations worldwide. Since stepping down from that role in 2012, Hugo has acted as an independent senior advisor with several multinational companies, private equity groups and consulting firms primarily in the animal health sector. Hugo brings a wealth of international experience to the board of Benchmark, alongside his expertise in aggressively growing businesses and in the commercialisation of medicines and animal health products. Hugo is based in the United States.

 

Yngve Myhre (48) has more than 20 years experience in the aquaculture sector as a senior executive, adviser and investor. Yngve was chief executive of leading Norwegian salmon producer Salmar, and of international white fish supplier Aker Seafood during periods of successful growth. He is now chairman of Chilean salmon producer Nova Austral, recently acquired by Cargill, and sits on the boards of Mediterranean fish producer Andromeda and Norwegian aquaculture research institute Nofima. Yngve also acts as strategic adviser to investors in the aquaculture sector. Yngve has a very strong track record in Benchmark's focus area of aquaculture, both in the Norwegian and international markets. Yngve is based in Norway.

 

Information in respect of Hugo Wahnish and Yngve Myhre, as required by Rule 17 and Schedule 2(g) of the AIM Rules for Companies, is set out below.

 

Benchmark's Chairman, Alex Hambro, commented:

 

"We are delighted to welcome Hugo and Yngve to the Board of Benchmark. Their combined expertise and experience in the aquaculture and pharmaceutical industries will broaden the Board of Benchmark as the Company seeks to maximise value from its unique portfolio of products and technologies.

 

 The Board of Benchmark carried out an extensive international search to bring to the Board additional leading international industry and commercialisation expertise. Attracting Hugo and Yngve is a testament of the strength of our industry standing, our technology platform and our potential."

 

 

Additional information:

 

Neither Hugo Wahnish nor Yngve Myhre hold any shares in the Company.

 

 

Hugo Wahnish's current directorships/partnerships:

 

Dinicola PartnersMaxima LLC

 

Yngve Myhre's current directorships/partnerships:

 

Rosøy AS

Nova Austral SA

Nova Austral Management Invest AS

Blåfjell AS

Blåfjell Holding

Aqua Site AS

Aqua Site Holding

Perseus Seafood LimitedHelgeland Adventure AS

 

Yngve Myhre's past directorships/partnerships (last 5 years):

 

SalMar ASA

Albain Midco Norway AS (EWOS Group)

Arnarlax and Kvitholmen AS

Trænafestivalen

 

There is no further information to be disclosed pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

- Ends -

 

 For further information, please contact:

 

Benchmark Holdings plc Tel: 020 7920 3150

Malcolm Pye, CEO

Ivonne Cantu, Investor Relations Director

Rachel Aninakwah, Communications

 

Numis Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

 

Tavistock Tel: 020 7920 3150

Sophie Praill

 

 

Notes to Editors:

 

Benchmark challenges the status quo in aquaculture.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping food producers take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues facing producers primarily in the aquaculture sector.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 September 2017, Benchmark employed 952 people.

 

For further information on Benchmark please visit www.benchmarkplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABLBDBIXGBGRX
Date   Source Headline
31st Mar 20237:00 amRNSTotal Voting Rights
21st Mar 20235:33 pmRNSShare Premium Reduction
21st Mar 20237:00 amRNSBlock Listing Six Monthly Return
17th Mar 20236:09 pmRNSHolding(s) in Company
2nd Mar 202311:12 amRNSDirector Dealings
28th Feb 20239:00 amRNSTotal Voting Rights
28th Feb 20237:00 amRNSQ1 Results
17th Feb 20237:00 amRNSAcquisition of remaining minority interest
16th Feb 20236:03 pmRNSResult of AGM
14th Feb 202311:45 amRNSNotice of Q1 Results
31st Jan 20237:00 amRNSTotal Voting Rights
27th Jan 20234:40 pmRNSSecond Price Monitoring Extn
27th Jan 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
11th Jan 20238:00 amRNSPosting of Notice of AGM
30th Dec 20227:00 amRNSTotal Voting Rights
16th Dec 20229:58 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSFirst Day of Trading on Euronext Growth Oslo
14th Dec 20229:15 amRNSCompletion of private placement & retail offering
13th Dec 20224:30 pmRNSSufficient number of shares in VPS
6th Dec 20226:21 pmRNSSuccessful private placement and retail offering
6th Dec 20227:00 amRNSLast day of bookbuilding and application period
1st Dec 20223:36 pmRNSPublication of Annual Report and Notice of AGM
1st Dec 202210:58 amRNSStatus of bookbuilding
1st Dec 20227:00 amRNSProspectus & Commencement of Bookbuilding Period
30th Nov 202210:00 amRNSTotal Voting Rights
30th Nov 20227:01 amRNSPrivate Placing & Retail Offering
30th Nov 20227:00 amRNSQ4 Results
30th Nov 20227:00 amRNSFull Year Results
25th Nov 20227:00 amRNSNotice of Results
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20224:35 pmRNSChange of Registered Office
31st Oct 20227:00 amRNSTotal Voting Rights
24th Oct 20227:00 amRNSTrading Update
19th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20224:35 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSTotal Voting Rights
21st Sep 20227:00 amRNSBlock listing Six Monthly Return
20th Sep 20227:00 amRNSBenchmark hosts Capital Markets Day today
16th Sep 20227:00 amRNSRefinances the Company's existing debt
15th Sep 20224:35 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSFixed Income Investor Meetings
31st Aug 20227:00 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSQ3 Results
1st Aug 20227:00 amRNSNotice of Q3 Results
29th Jul 20227:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.